ioGenetics is developing Directed Biocide™ antibody fusions (DBAF) and specific microbiocides as an alternative to antibiotics. Whereas traditional antibiotics act on metabolic pathways, DBAF target naturally occurring microbiocides to the microorganism to cause lethal structural damage. By using antibodies to specifically target organisms, very low concentrations of the drug can be highly effective by delivering a microbiocide “payload” precisely to the point of action. Two technology platforms underpin our rational development pathway: immunoinformatics and recombinant protein expression.

The company has successfully developed effective products for combatting cryptosporidiosis and antibiotic resistant
Staphylococcus (“MRSA”) and is now targeting other organisms where antibiotic resistance is a growing problem, such as Strep. pneumoniae.

Cryptosporidiosis is a serious protozoan diarrheal disease of children and adults.  Cryptosporidiosis has been shown to be second only to rotavirus in as a cause of diarrheal disease in children in developing countries and causes more deaths.  It causes travelers’ diarrhea and sporadic large outbreaks in the United States, often associate with water-borne exposure. ioGenetics has developed DBAF which are delivered orally, a pioneering approach in the delivery of macromolecules.

Antibiotic resistant
Staphylococcus, commonly known as MRSA, are an increasing cause of secondary hospital acquired disease, contributing to extended hospital stays and costs, and are increasingly emerging as a “community acquired disease” prevalent in the general population. Multiple different drugs with different modes of action will be needed to combat this growing threat.

ioGenetics’ development pipeline is addressing other organisms where antibiotic resistance is emerging.
19 March 2016
Preprint publication Antibody mimicry in Zika infections.
Click for details.

02 March 2016
Published by PLOS Neglected Tropical Diseases, Zika Response Group Review Paper on Countermeasure Development

Click for details.
Click here for ioGenetics immunoinformatics.